Hui P. Luo
17 Yongwai Zheng Road
Nanchang, China
Nanchang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.
Journal: Future oncology (London, England)
Published: June 03, 2026
Regulatory networks of non-coding RNAs in renal cell carcinogenesis and therapeutic intervention strategies.
Journal: World journal of urology
Published: April 29, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Journal: Lancet (London, England)
Published: April 23, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: April 22, 2026
Epigenetic silencing of PHYHD1 in hepatocellular carcinoma revealed by integrated multi-omics analysis.
Journal: Frontiers in genetics
Published: April 06, 2026
Cucurbitacin B targets PPAT to suppress de novo purine biosynthesis in esophageal squamous cell carcinoma.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: January 26, 2026
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.
Journal: Cancer cell
Published: November 25, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 22, 2025
The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study.
Journal: Therapeutic advances in medical oncology
Published: August 06, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: July 23, 2025
Evaluation of inflammation-mediated cancer progression during FLASH and conventional irradiation-induced lung injury.
Journal: Clinical science (London, England : 1979)
Published: June 25, 2025
Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study.
Journal: Cancer immunology, immunotherapy : CII
Published: June 19, 2025
Last Updated: 09/26/2026